Your browser doesn't support javascript.
loading
[Schisandrin C improves acetaminophen-induced liver injury in mice by regulating Nrf2 signaling pathway].
Dai, Wen-Zhang; Bai, Zhao-Fang; He, Ting-Ting; Zhan, Xiao-Yan; Li, Qiang; Zhao, Jing; Xiao, Xiao-He.
Afiliação
  • Dai WZ; School of Pharmacy, Hunan University of Chinese Medicine Changsha 410208, China Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
  • Bai ZF; Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
  • He TT; Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
  • Zhan XY; Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
  • Li Q; Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
  • Zhao J; School of Pharmacy, Hunan University of Chinese Medicine Changsha 410208, China.
  • Xiao XH; School of Pharmacy, Hunan University of Chinese Medicine Changsha 410208, China Department of Hepatology, the Fifth Medical Center of Chinese PLA General Hospital Beijing 100039, China.
Zhongguo Zhong Yao Za Zhi ; 47(19): 5299-5305, 2022 Oct.
Article em Zh | MEDLINE | ID: mdl-36472037
ABSTRACT
Excess acetaminophen(APAP) can be converted by the cytochrome P450 system to the toxic metabolite N-acetyl-p-benzoquinoneimine(NAPQI), which consumes glutathione(GSH). When GSH is depleted, NAPQI covalently binds with proteins, inducing mitochondrial dysfunction and oxidative stress and thereby leading to hepatotoxicity. Schisandrin C(SinC) is a dibenzocyclooctadiene derivative isolated from Schisandra chinensis. Although there is some evidence showing that SinC has hepatoprotective activity, its protective effect and mechanism on APAP-induced liver injury remain unclear. In this paper, an acute liver injury mouse model was established by intraperitoneal injection of APAP at a dose of 400 mg·kg~(-1) to evaluate the effect of SinC administration on the APAP-induced liver injury and its mechanism through an animal experiment. At the same time, a potential candidate drug was provi-ded for traditional Chinese medicine(TCM) prevention and treatment of overdose APAP-induced liver injury. In the APAP-induced liver injury mouse model, we found that SinC can relieve hepatic histopathological lesions and significantly reduce the activities of alanine aminotransferase(ALT), aspartate aminotransferase(AST) and alkaline phosphatase(ALP). It was also capable of increasing the content of GSH and superoxide dismutase(SOD) and decreasing the levels of total bilirubin(TBIL), direct bilirubin(DBIL), malondialdehyde(MDA), interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α). Further analysis showed that SinC decreased the content of CYP2 E1 in liver tissues at protein and mRNA levels and increased nuclear factor erythroid 2-related factor 2(Nrf2) and the expression of its downstream targets(including HO-1, NQO1 and GCLC). Taken together, the above results indicate that SinC can alleviate APAP-induced liver injury by reducing the expression of CYP2 E1, suppressing apoptosis, improving inflammatory response and activating the Nrf2 signaling pathway to inhibit oxidative stress.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Hepática Induzida por Substâncias e Drogas / Doença Hepática Crônica Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Assunto da revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Hepática Induzida por Substâncias e Drogas / Doença Hepática Crônica Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: Zh Revista: Zhongguo Zhong Yao Za Zhi Assunto da revista: FARMACOLOGIA / TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China